Skip to content
TrialScanner

NCT00589875

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Phase 2CompletedCADLLead

Registry record

Lead sponsor
Candel Therapeutics, Inc.
Conditions
Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; High Grade Glioma
Primary completion
Dec 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00589875 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00589875: Phase 2a Study of CAN-2409... | TrialScanner